Active, not recruitingNCT04882475
Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Francesca Maria QuagliaAzienda Ospedaliera Universitaria (AOU) Integrata di Verona - Unità Operativa di Ematologia
- Enrollment
- 160 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2023 – 2026
Study locations (16)
- ASST Grande Ospedale Metropolitano Niguarda, Milan, MI, Italy
- AOU Senese - U.O.C. Ematologia, Siena, SI, Italy
- Centro Riferimento Oncologico - S.O.C. Oncologia Medica A, Aviano, Italy
- ASST Spedali Civili di Brescia - Ematologia, Brescia, Italy
- A.O. S. Croce e Carle, Cuneo, Italy
- Azienda Ospedaliera Universitaria Careggi- Unità funzionale di ematologia, Florence, Italy
- AOU Maggiore della Carità di Novara - SCDU Ematologia, Novara, Italy
- AOU di Padova - Ematologia, Padova, Italy
- Ospedale Guglielmo da Saliceto - U.O.Ematologia, Piacenza, Italy
- Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia - Ematologia, Reggio Emilia, Italy
- A.O.U. Citta della Salute e della Scienza di Torino- Ematologia Universitaria, Torino, Italy
- Ospedale Ca' Foncello - S.C di Ematologia, Treviso, Italy
- Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - SC Ematologia, Trieste, Italy
- Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) - SOC Clinica Ematologica, Udine, Italy
- AOU Integrata di Verona - U.O. Ematologia, Verona, Italy
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04882475 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06675123Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGPHASE2NCT07082686A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)Beijing InnoCare Pharma Tech Co., Ltd.
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT07199296Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentRuijin Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University